Episode 13: Dr Liz Dallimore, CEO of Argenica Therapeutics
Hey everyone and welcome to another big episode of Euroz Hartleys “Finding the Front”.
This episode is just such an absolute cracker! We have such an awesome opportunity to spend some time in conversation with a true leader in their field – Life Sciences, Technology and Data Strategy, Commercialisation and Innovation specialist Dr Liz Dallimore, the inaugural CEO of Argenica Therapeutics, stock code AGN. Argenica Therapeutics is a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke.
Liz grew up with science as part of her life. Her father achieved a PhD in nuclear physics from Oxford University and her love of science grew from an early stage. She then went on to graduate from the University of WA and Oxford University with a PhD in Nueroscience. In this podcast Liz speaks openly, drawing from her more than 20 years of experience and her deep understanding and highly educated insights. This results in a seriously thought provoking discussion into the human brain, the effect of stroke on the human brain, and the business side of the life sciences and Australian biotechnology sector – a sector which she is very passionate about.
Liz is also a mother of three kids who during her career was awarded winner of the 2019 Women in Technology WA Tech + Awards, was featured in the Sunday Times STM Magazine for International Women’s Day 2020 as one of three WA Women making a difference and was selected as 1 of 25 Australian Female Leaders in the STEM for 2022 Federal Government Women in Leadership Development Program as well as Co-Founding a Medical Device Start Up Company and being the inaugural CEO of an ASX listed Biotech Company. She has numerous Board and Advisory roles including a Non-Executive Director role with the National Energy Resources Australia organisation, a General Council role with the WA Chamber of Commerce and Industry, and with the Stan Perron Charitable Foundation, being part of the Research Investment Advisory Panel.
We hope you enjoy.